Randomized Controlled Trial of the Immunogenicity and Safety of a Serum-Free Purified Vero Rabies Vaccine (PVRV-NG2) Using a Simulated Postexposure Zagreb Regimen With Human Rabies Immunoglobulin in Adults in Thailand
PVRV-NG2 showed acceptable safety and immunogenicity profiles when co-administered with HRIG in a simulated PEP Zagreb regimen in healthy adults in Thailand.
Authors
- Kriengsak Limkittikul (ORCID: https://orcid.org/0000-0002-2990-6530)
- Danaya Chansinghakul
- Terapong Tantawichien (ORCID: https://orcid.org/0000-0003-1970-5118)
- Carina Frago (ORCID: https://orcid.org/0000-0003-2450-6420)
- Winai Ratanasuwan (ORCID: https://orcid.org/0000-0003-2602-5153)
- Andrea-Clemencia Pineda-Peña (ORCID: https://orcid.org/0000-0003-1937-0506)
- Françoise Guinet-Morlot
- Céline Petit (ORCID: https://orcid.org/0000-0002-9829-7011)
- Yuancheng Wang (ORCID: https://orcid.org/0000-0002-7508-1920)
Institutions
- Thai Red Cross Society (TH)
- Siriraj Hospital (TH)
- Chulalongkorn University (TH)
- Queen Saovabha Memorial Institute (TH)
- Mahidol University (TH)
- Global Strategy Group (US)
- Sanofi (France) (FR)
- Mahidol Oxford Tropical Medicine Research Unit (TH)
- Sanofi (China) (CN)
- Biostatistical Consulting (United States) (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1093/ofid/ofae633
- Primary Topic
- Rabies epidemiology and control
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Sanofi Australia